Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

NCT00475956 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: AZD2171
DRUG: AZD0530

Sponsor

AstraZeneca